Appetite suppressants reshape how Americans consume—and what they buy to manage the consequences.
As millions of Americans turn to GLP-1 weight-loss medications that suppress their appetite for sweets, Hershey has found an unexpected beneficiary in its mint and gum business — a reminder that markets rarely lose without also finding somewhere new to win. The phenomenon, colloquially called 'Ozempic breath,' points to a quiet truth: when human behavior shifts at scale, even the disrupted adapt. What began as a pharmaceutical revolution in how people eat has quietly become a commercial opportunity in how they manage the aftermath.
- GLP-1 drugs like Ozempic and Wegovy are eroding traditional candy and snack sales by suppressing appetite across millions of American consumers.
- A reported side effect — persistent bad breath linked to gastrointestinal disturbances — is driving unexpected demand for breath fresheners among drug users.
- Hershey's Ice Breakers mints and gum surged 8% in the first quarter, with CEO Kirk Tanner directly crediting GLP-1 users as a key growth driver.
- Medical experts remain cautious: halitosis isn't officially listed as a clinical side effect, though 9% of trial participants reported burping and nausea affected over 40%.
- Hershey's portfolio is quietly reorienting — mints and gum shifting from impulse indulgences to functional necessities for a pharmacologically reshaped consumer base.
Hershey's spring earnings call delivered a paradox: even as weight-loss drugs suppress Americans' appetite for candy, the company's mint and gum business is booming. CEO Kirk Tanner pointed to an 8 percent sales jump in Ice Breakers, driven not by snacking but by what users have come to call 'Ozempic breath.'
GLP-1 medications like Ozempic and Wegovy work by mimicking a fullness hormone, reducing appetite effectively enough to dent traditional snack sales. But they also bring gastrointestinal side effects — nausea, burping, and a fishy-smelling halitosis that some users report. Novo Nordisk doesn't officially list bad breath among adverse effects, yet its own clinical trials found 9 percent of participants experienced burping and over 40 percent reported nausea. The oral consequences of those disturbances remain under active study.
Medical professionals are careful not to declare it a formal diagnosis, and the link between GLP-1 drugs and halitosis isn't universal. But the market signal has been clear enough for Hershey. Mints and gum — once casual checkout-counter impulse buys — are becoming something closer to functional remedies for a growing population managing the side effects of eating less.
The story reflects a durable pattern in consumer markets: large-scale behavioral shifts rarely destroy opportunity outright — they relocate it. Hershey absorbs losses in chocolate and gains in breath fresheners, its portfolio quietly bending toward wherever people still reach for its products. As GLP-1 adoption continues to rise, that reshaping of both appetite and consequence is only likely to deepen.
Hershey's earnings call this spring brought an unusual bright spot: the company's mint and gum business is thriving, even as millions of Americans use weight-loss drugs that suppress their appetite for candy altogether. The paradox reveals something about how markets adapt when consumer behavior shifts in unexpected ways.
During the first-quarter earnings presentation, CEO Kirk Tanner highlighted that Ice Breakers mints and gum posted an 8 percent sales increase. The driver, he explained, wasn't traditional snacking. Instead, Hershey is benefiting from what's become known as "Ozempic breath"—a side effect that's emerged as GLP-1 weight-loss medications like Ozempic and Wegovy have become mainstream. While these drugs work by reducing appetite, they also appear to trigger bad breath in some users, creating demand for products designed to freshen breath rather than satisfy hunger.
The mechanism is straightforward enough. GLP-1 medications suppress appetite by mimicking a hormone that signals fullness to the brain. They work. People eat less. Snack sales decline. But the drugs also come with gastrointestinal side effects, and among them is halitosis—a fishy-smelling odor that can accompany burping or general bad breath. Dr. Neha Lalani, speaking to the medical information site Healthline, described the phenomenon plainly: a fishy smell in burps or breath itself. It's not an official side effect listed by manufacturers. Novo Nordisk, which makes both Ozempic and Wegovy, doesn't include halitosis in its documented adverse effects. But the company's own clinical trials tell a revealing story. About 9 percent of trial participants reported eructation—burping—as a side effect. More than 40 percent experienced nausea. Nearly 25 percent vomited. The oral hygiene consequences of these gastrointestinal disturbances are still being studied.
Medical professionals are cautious about calling it a clinical diagnosis. The effect isn't universal, and the relationship between the drugs and bad breath remains an area of ongoing research. But for Hershey, the market signal is clear. As appetite suppressants reshape how Americans consume traditional snacks, they're simultaneously creating a new category of functional snacking—products bought not for pleasure but for necessity. Mints and gum, once impulse purchases at checkout counters, have become something closer to medication for a growing population.
The shift illustrates a broader truth about consumer markets: when millions of people change their behavior, even in ways that seem to hurt a business, new opportunities emerge elsewhere. Hershey loses volume in chocolate and candy. It gains it in breath fresheners. The company's overall snacking portfolio adapts. What matters is that people still reach for Hershey products—just different ones, for different reasons. As GLP-1 adoption continues to climb, that dynamic will likely deepen, reshaping not just what Americans eat, but what they buy to manage the consequences of eating less.
Citações Notáveis
The company has seen strong demand for gum and mint products as the category benefits from functional snacking tailwinds, including GLP-1 adoption.— Kirk Tanner, Hershey CEO
Ozempic breath refers to a fishy smell in burps or bad breath.— Dr. Neha Lalani, medical information provider Healthline
A Conversa do Hearth Outra perspectiva sobre a história
So Hershey's selling fewer chocolate bars but more mints. That seems like a wash, doesn't it?
Not quite. The margin story is different. Mints and gum are positioned as functional products—you're buying them for a reason, not just because you want candy. That changes pricing power. And it's a category that was already growing before GLP-1 drugs arrived.
But is the bad breath thing real, or is Hershey just spinning a story to explain why mints are selling?
The clinical data supports it. Nine percent of trial participants reported burping. Forty percent had nausea. When your stomach is in that state, breath suffers. It's not a mystery. Whether it's the primary driver of mint sales—that's harder to prove. But Tanner wouldn't mention it on an earnings call if the correlation wasn't there.
What happens if GLP-1 adoption plateaus? Does the mint boom end?
Possibly. But by then, the category will have normalized. Mints will have moved from impulse buy to routine purchase for a subset of the population. That's a permanent shift in consumer behavior, even if the growth rate slows.
Are other companies seeing this?
Almost certainly. Any company in oral care, breath fresheners, or functional snacking is probably watching this closely. Hershey just happened to be the first to say it out loud.